Topical tacrolimus or pimecrolimus

Phase 3Small molecule

Topical tacrolimus or pimecrolimus is one of 6 small molecule programs targeting Dermatitis, Atopic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dermatitis, AtopicRecruiting

Dermatitis, AtopicPhase 3

Recruiting

Competition

Competitive Landscape

9 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

Amlitelimab

Sanofi

Phase 3

3 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

2 3

Topical Corticosteroids

Sanofi

Phase 3

2 4

Topical tacrolimus or pimecrolimus

Sanofi

Phase 3

1 5

JNJ-95475939

Johnson & Johnson

Phase 2

1 6

JNJ-95597528

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Dermatitis, Atopic

NCT06241118

Clinical

Trials by Indication[1]

Dermatitis, Atopic1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT06241118·636 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topical tacrolimus or pimecrolimus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical tacrolimus or pimecrolimus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical tacrolimus or pimecrolimus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Topical tacrolimus or pimecrolimus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Dermatitis, Atopic1 trial

References

Drug Info

Quick Facts

Related News